


# RESEARCH REPORT



## GENOMIC CANCER PANEL AND PROFILING MARKETS BY CANCER, BY APPLICATION, BY TISSUE AND BY GENE TYPE WITH SCREENING POTENTIAL MARKET SIZE, CUSTOMIZED FORECASTING/ANALYSIS, AND EXECUTIVE AND CONSULTANT GUIDES 2022-2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

1	Market Guides .....	25
1.1	Cancer Panel Market - Strategic Situation Analysis .....	26
1.2	Large Comprehensive Cancer Panel Market - Situation Analysis .....	28
1.3	Guide for Executives, Marketing, Sales and Business Development Staff .....	30
1.4	Guide for Management Consultants and Investment Advisors.....	32
1.5	Market Size and Shares – Large Comprehensive .....	33
2	Introduction and Market Definition .....	35
2.1	What are Cancer Gene Panels and Profiling? .....	36
2.2	The Sequencing Revolution .....	39
2.3	Market Definition .....	41
2.3.1	Revenue Market Size.....	41
2.4	Methodology.....	42
2.4.1	Authors .....	42
2.4.2	Sources .....	43
2.5	Perspective: Healthcare and the IVD Industry .....	44
2.5.1	Global Healthcare Spending .....	44
2.5.2	Spending on Diagnostics .....	45
2.5.3	Important Role of Insurance for Diagnostics .....	46
3	Market Overview.....	48

3.1	Players in a Dynamic Market.....	49
3.1.1	Academic Research Lab .....	50
3.1.2	Diagnostic Test Developer.....	50
3.1.3	Instrumentation Supplier .....	50
3.1.4	Distributor and Reagent Supplier .....	51
3.1.5	Independent Testing Lab.....	51
3.1.6	Public National/regional lab .....	52
3.1.7	Hospital lab .....	52
3.1.8	Physician Office Labs .....	53
3.1.9	Audit Body .....	53
3.1.10	Certification Body.....	53
3.2	Oncogenomics .....	55
3.2.1	Carcinogenesis.....	55
3.2.2	Chromosomes, Genes and Epigenetics.....	57
3.2.2.1	Chromosomes.....	57
3.2.2.2	Genes .....	59
3.2.2.3	Epigenetics.....	62
3.2.3	Cancer Genes.....	63
3.2.4	Germline vs Somatic .....	65
3.2.5	Gene Panels, Single Gene Assays and Multiplexing .....	66
3.2.6	Genomic Profiling.....	67
3.2.7	The Comprehensive Assay .....	68
3.2.8	Changing Clinical Role .....	68
3.2.9	The Cancer Screening Market Opportunity.....	70

- 3.3 Cancer Management vs. Diagnosis..... 71
  - 3.3.1 The Role of Risk Assessment ..... 71
  - 3.3.2 Diagnosis ..... 71
  - 3.3.3 Managing ..... 72
  - 3.3.4 Monitoring..... 72
- 3.4 Phases of Adoption – Looking into The Future ..... 73
- 3.5 Structure of Industry Plays a Part..... 74
  - 3.5.1 Hospital Testing Share ..... 74
  - 3.5.2 Economies of Scale..... 74
    - 3.5.2.1 Hospital vs. Central Lab..... 75
  - 3.5.3 Physician Office Lab's..... 76
  - 3.5.4 Physician's and POCT ..... 77
- 3.6 Currently Available Large Comprehensive Assays ..... 77
- 3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing..... 80
  - 3.7.1 Medicare Profile Pricing..... 80
  - 3.7.2 Whole Exome Sequencing ..... 80
- 4 Market Trends .....82
  - 4.1 Factors Driving Growth ..... 83
    - 4.1.1 Level of Care ..... 83
    - 4.1.2 Companion Dx ..... 84
    - 4.1.3 Immuno-oncology..... 84
    - 4.1.4 Liability..... 84
    - 4.1.5 Aging Population..... 84
  - 4.2 Factors Limiting Growth ..... 86

4.2.1	State of knowledge.....	86
4.2.2	Genetic Blizzard.....	87
4.2.3	Protocol Resistance.....	87
4.2.4	Regulation and coverage.....	87
4.3	Instrumentation and Automation.....	88
4.3.1	Instruments Key to Market Share.....	88
4.3.2	Bioinformatics Plays a Role.....	88
4.4	Diagnostic Technology Development.....	89
4.4.1	Next Generation Sequencing Fuels a Revolution.....	90
4.4.2	Single Cell Genomics Changes the Picture.....	91
4.4.3	Pharmacogenomics Blurs Diagnosis and Treatment.....	92
4.4.4	CGES Testing, A Brave New World.....	92
4.4.5	Biochips/Giant magneto resistance based assay.....	93
5	Cancer Panels & Profiles Recent Developments.....	94
5.1	Recent Developments – Importance and How to Use This Section.....	95
5.1.1	Importance of These Developments.....	95
5.1.2	How to Use This Section.....	95
5.2	Genetron Health Adds New Assays to Pipeline.....	95
5.3	Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay.....	98
5.4	Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test ...	99
5.5	Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay.....	100
5.6	Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs.....	102
5.7	Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role.....	104

5.8	Labcorp, CCORN Partner for Precision Oncology .....	111
5.9	Dante Labs Acquires Cambridge Cancer Genomics .....	112
5.10	Celemics, Strand Partner on Integrated Platform for NGS Analysis .....	113
5.11	Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries .....	113
5.12	Burning Rock Revenues Rise .....	119
5.13	Caris Life Sciences to Expand Liquid Biopsy Testing .....	121
5.14	OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence.....	124
5.15	Intermountain and Myriad Combine Test Offering .....	128
5.16	Illumina, Geneseeq to Offer Cancer Testing Kits in China.....	133
5.17	Exact Sciences to Offer End-to-End Cancer Testing .....	134
5.18	Guardant Health Turns to Tumor Tissue Sequencing .....	137
5.19	Tempus Inks Oncology Testing Collaboration With Bayer.....	141
5.20	Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform 142	
5.21	Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test .....	143
5.22	Metastatic Cancer Markers Identified in Clinical WGS Study.....	144
5.23	Stitch Bio Bets on CRISPR Tech .....	147
5.24	Bayer, LifeLabs Launch Free NTRK Genetic Testing Program .....	151
5.25	Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx 152	
5.26	Progress, Challenges in Liquid Biopsy Reimbursement.....	153
5.27	Israeli Startup Curesponse Raises \$6M.....	157
5.28	Invitae, ArcherDX Merge to Advance Precision Oncology Offerings .....	158
5.29	MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution 159	



5.30	NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program.....	159
5.31	Germline Results Guides Precision Therapy in Advanced Cancer .....	160
5.32	FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics .....	165
5.33	ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers 166	
5.34	Labs Reporting Cancer Risk Mutations from Tumor Testing .....	167
5.35	Users Begin Integrating Genomics Data for Clinical Decision Support.....	175
5.36	Fujitsu Improves Efficiency in Cancer Genomic Medicine .....	180
5.37	Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results	182
5.38	Universal Genetic Testing for All Breast Cancer Patients .....	183
5.39	Exact Sciences buys Genomic Health .....	184
5.40	Multi-Gene Liquid Biopsy Breast Cancer Panel .....	186
5.41	Thrive to Develop Earlier Detection of Multiple Cancer Types.....	186
5.42	New Gene Panel Identifies High Risk Prostate Cancer .....	188
5.43	Guardant Health Liquid Biopsy Test to be Covered by EviCore .....	190
5.44	Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services.....	191
5.45	Natera Commercializes Tumor Whole Exome Sequencing from Plasma.....	192
5.46	Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance .....	193
6	Profiles of Key Players.....	195
6.1	10x Genomics, Inc.....	196
6.2	Abbott Diagnostics .....	197
6.3	AccuraGen Inc. ....	199
6.4	Adaptive Biotechnologies.....	200
6.5	Aethlon Medical .....	201

6.6	Agena Bioscience, Inc. ....	202
6.7	Agilent/Dako .....	204
6.8	Anchor Dx.....	206
6.9	ANGLE plc.....	207
6.10	ApoCell, Inc.....	208
6.11	ArcherDx, Inc.....	209
6.12	ARUP Laboratories.....	210
6.13	Asuragen.....	212
6.14	AVIVA Biosciences .....	214
6.15	Baylor Miraca Genetics Laboratories .....	215
6.16	Beckman Coulter Diagnostics.....	216
6.17	Becton, Dickinson and Company .....	217
6.18	BGI Genomics Co. Ltd .....	219
6.19	Bioarray Genetics.....	221
6.20	Biocartis.....	222
6.21	Biocept, Inc.....	223
6.22	Biodesix Inc. ....	225
6.23	BioFluidica.....	226
6.24	BioGenex .....	227
6.25	BioIVT .....	229
6.26	Biolidics Ltd.....	230
6.27	bioMérieux Diagnostics.....	231
6.28	Bioneer Corporation .....	233
6.29	Bio-Rad Laboratories, Inc.....	235

6.30	Bio-Reference Laboratories.....	237
6.31	Bio-Techne .....	238
6.32	Bioview .....	239
6.33	Bolidics .....	240
6.34	Boreal Genomics.....	241
6.35	Bristol-Myers Squibb.....	242
6.36	Burning Rock.....	244
6.37	Cancer Genetics.....	245
6.38	Cardiff Oncology .....	247
6.39	Caris Molecular Diagnostics .....	248
6.40	Castle Biosciences, Inc. ....	249
6.41	Celemics .....	250
6.42	CellMax Life .....	251
6.43	Cepheid (Danaher) .....	252
6.44	Charles River Laboratories.....	254
6.45	Chronix Biomedical.....	255
6.46	Circulogene.....	256
6.47	Clinical Genomics .....	257
6.48	Cynvenio.....	258
6.49	Cytolumina Technologies Corp. ....	259
6.50	CytoTrack.....	260
6.51	Datar Cancer Genetics Limited.....	261
6.52	Diagnologix LLC.....	262
6.53	Diasorin S.p.A.....	263

6.54	Enzo Life Sciences, Inc. ....	265
6.55	Epic Sciences.....	267
6.56	Epigenomics AG.....	268
6.57	Eurofins Scientific .....	269
6.58	Exact Sciences .....	271
6.59	Exosome Diagnostics .....	272
6.60	Exosome Sciences.....	273
6.61	Fabric Genomics .....	274
6.62	Fluidigm Corp .....	275
6.63	Fluxion Biosciences.....	276
6.64	Foundation Medicine .....	277
6.65	Freenome.....	278
6.66	FUJIFILM Wako Diagnostics.....	279
6.67	GeneFirst Ltd. ....	280
6.68	Genetron Holdings .....	281
6.69	GenomOncology.....	282
6.70	GILUPI Nanomedizin.....	283
6.71	Grail, Inc.....	284
6.72	Guardant Health .....	285
6.73	HaliuDx .....	286
6.74	HansaBiomed .....	287
6.75	HeiScreen.....	288
6.76	Helomics.....	289
6.77	Horizon Discovery .....	290

6.78	HTG Molecular Diagnostics .....	292
6.79	iCellate.....	293
6.80	Illumina .....	294
6.81	Incell Dx.....	295
6.82	Inivata .....	296
6.83	Integrated Diagnostics .....	297
6.84	Invitae Corporation.....	298
6.85	Invivogen .....	300
6.86	Invivoscribe .....	301
6.87	Janssen Diagnostics .....	302
6.88	MDNA Life SCIENCES, Inc.....	303
6.89	MDx Health .....	304
6.90	Menarini Silicon Biosystems.....	305
6.91	Millipore Sigma .....	306
6.92	Miltenyi Biotec .....	307
6.93	MIODx.....	308
6.94	miR Scientific.....	309
6.95	Molecular MD .....	310
6.96	MyCartis .....	311
6.97	Myriad Genetics/Myriad RBM .....	312
6.98	NantHealth, Inc. ....	313
6.99	Natera .....	314
6.100	NeoGenomics .....	315
6.101	New Oncology .....	316

6.102	NGeneBio.....	317
6.103	Novogene Bioinformatics Technology Co., Ltd.....	319
6.104	Oncocyte.....	321
6.105	OncoDNA .....	322
6.106	Ortho Clinical Diagnostics .....	323
6.107	Oxford Nanopore Technologies .....	324
6.108	Panagene.....	325
6.109	Perkin Elmer.....	326
6.110	Personal Genome Diagnostics.....	328
6.111	Personalis.....	329
6.112	Precipio .....	330
6.113	PrecisionMed.....	331
6.114	Promega .....	332
6.115	Qiagen Gmbh .....	334
6.116	Rarecells SAS.....	336
6.117	RareCyte.....	337
6.118	Roche Molecular Diagnostics .....	338
6.119	ScreenCell .....	340
6.120	Sense Biodetection .....	341
6.121	Serametrix.....	342
6.122	Siemens Healthineers .....	343
6.123	Silicon Biosystems.....	345
6.124	simfo GmbH .....	346
6.125	Singlera Genomics Inc.....	347

6.126	Singulomics .....	348
6.127	SkylineDx .....	350
6.128	Stratos Genomics .....	351
6.129	Sysmex Inostics.....	352
6.130	Tempus Labs, Inc. ....	353
6.131	Thermo Fisher Scientific Inc.....	354
6.132	Thrive Earlier Detection .....	357
6.133	Todos Medical.....	358
6.134	Variantyx.....	359
6.135	Volition .....	360
6.136	Vortex Biosciences .....	361
7	The Global Market for Cancer Gene Panels and Profiles.....	362
7.1	Global Market Overview by Country .....	363
7.1.1	Table – Global Market by Country.....	363
7.1.2	Chart - Global Market by Country.....	364
7.2	Global Market by Cancer Type - Overview.....	365
7.2.1	Table – Global Market by Cancer Type .....	365
7.2.2	Chart – Global Market by Cancer Type – Base/Final Year Comparison .....	366
7.2.3	Chart – Global Market by Cancer Type – Base Year .....	367
7.2.4	Chart – Global Market by Cancer Type – Final Year.....	368
7.2.5	Chart – Global Market by Cancer Type – Share by Year .....	369
7.2.6	Chart – Global Market by Cancer Type – Segment Growth .....	370
7.3	Global Market by Application - Overview.....	371
7.3.1	Table – Global Market by Application .....	371

7.3.2	Chart – Global Market by Application – Base/Final Year Comparison .....	372
7.3.3	Chart – Global Market by Application – Base Year .....	373
7.3.4	Chart – Global Market by Application – Final Year .....	374
7.3.5	Chart – Global Market by Application – Share by Year.....	375
7.3.6	Chart – Global Market by Application – Segment Growth .....	376
7.4	Global Market by Tissue - Overview .....	377
7.4.1	Table – Global Market by Tissue .....	377
7.4.2	Chart – Global Market by Tissue – Base/Final Year Comparison .....	378
7.4.3	Chart – Global Market by Tissue – Base Year .....	379
7.4.4	Chart – Global Market by Tissue – Final Year .....	380
7.4.5	Chart – Global Market by Tissue – Share by Year .....	381
7.4.6	Chart – Global Market by Tissue – Segment Growth.....	382
7.5	Global Market Germline & Somatic - Overview.....	383
7.5.1	Table – Global Market Germline & Somatic .....	383
7.5.2	Chart – Global Market Germline & Somatic – Base/Final Year Comparison .....	384
7.5.3	Chart – Global Market Germline & Somatic – Base Year .....	385
7.5.4	Chart – Global Market Germline & Somatic – Final Year.....	386
7.5.5	Chart – Global Market Germline & Somatic – Share by Year.....	387
7.5.6	Chart – Global Market Germline & Somatic – Segment Growth .....	388
8	Global Cancer Gene Panels & Profiles Markets – By Type of Cancer.....	389
8.1	Comprehensive Panels & Profiles .....	390
8.1.1	Table Comprehensive Testing – by Country.....	390
8.1.2	Chart - Comprehensive Testing Growth.....	391
8.2	Breast Cancer Gene Testing .....	392



8.2.1	Table Breast Cancer Gene Testing – by Country .....	392
8.2.2	Chart - Breast Cancer Testing Growth.....	393
8.3	Colorectal Cancer Gene Testing .....	394
8.3.1	Table Colorectal Cancer Gene Testing – by Country.....	394
8.3.2	Chart - Colorectal Cancer Gene Testing Growth .....	395
8.4	Gynecological Cancer Gene Testing .....	396
8.4.1	Table Gynecological Cancer Gene Testing – by Country .....	396
8.4.2	Chart - Gynecological Cancer Gene Testing Growth.....	397
8.5	Blood Cancer Gene Testing.....	398
8.5.1	Table Blood Cancer Gene Testing – by Country .....	398
8.5.2	Chart - Blood Cancer Gene Testing Growth .....	399
8.6	Prostate Cancer Gene Testing.....	400
8.6.1	Table Prostate Cancer Gene Testing – by Country .....	400
8.6.2	Chart - Prostate Cancer Testing Growth .....	401
8.7	Lung Cancer Gene Testing .....	402
8.7.1	Table Lung Cancer Gene Testing – by Country.....	402
8.7.2	Chart - Lung Cancer Gene Testing Growth.....	403
8.8	Other Cancer Gene Testing.....	404
8.8.1	Table Other Cancer Gene Testing – by Country .....	404
8.8.2	Chart - Other Cancer Gene Testing Growth .....	405
9	Global Cancer Gene Panels & Profiles Markets – By Type of Application .....	406
9.1	Clinical Testing.....	407
9.1.1	Table Clinical Testing – by Country .....	407
9.1.2	Chart - Clinical Testing Growth.....	408

9.2	Pharmaceutical Testing.....	409
9.2.1	Table Pharmaceutical Testing – by Country .....	409
9.2.2	Chart - Pharmaceutical Testing Growth.....	410
9.3	Research Testing .....	411
9.3.1	Table Research Testing – by Country.....	411
9.3.2	Chart - Research Testing Growth .....	412
10	Global Cancer Gene Panels & Profiles Markets – By Tissue Type.....	413
10.1	Solid Tissue.....	414
10.1.1	Table Solid Tissue Testing – by Country .....	414
10.1.2	Chart – Solid Tissue Testing Growth .....	415
10.2	Liquid Tissue Testing .....	416
10.2.1	Table Liquid Tissue Testing – by Country .....	416
10.2.2	Chart - Liquid Tissue Testing Growth.....	417
11	Global Cancer Gene Testing Markets – Germline and Somatic .....	418
11.1	Global Market Somatic.....	419
11.1.1	Table Somatic – by Country .....	419
11.1.2	Chart - Somatic Testing Growth .....	420
11.2	Global Market Germline.....	421
11.2.1	Table Germline – by Country.....	421
11.2.2	Chart - Germline Testing Growth .....	422
12	Potential Market Opportunity Sizes.....	423
12.1	Potential Cancer Screening by Country: Lung, Breast & Colorectal.....	424
12.2	Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer.....	426
12.3	Potential Market Size - Cancer Diagnosis.....	428

12.4 Potential Market Size – Therapy Selection..... 430

13 Appendices .....432

13.1 Quarterly Actuals and Forecast Volumes and Revenues for Foundation Medicine and Guardant Health ..... 433

13.2 United States Medicare System: January 2022 Clinical Laboratory Fees Schedule . 438

13.3 FDA Approved Human Genetic Tests..... 540

13.4 Pharmacogenomic Biomarkers in Drug Labeling..... 546

13.5 FDA Approved Pharmacogenomics Tests ..... 569

## Table of Tables

Table 1 Market Shares .....	33
Table 2 Market Players by Type .....	49
Table 3 The Base Pairs.....	60
Table 4 Current Assays .....	77
Table 5 Relevant Pricing Table .....	80
Table 6 Five Factors Driving Growth.....	83
Table 7 Four Factors Limiting Growth .....	86
Table 8 Key Diagnostic Laboratory Technology Trends .....	89
Table 9 Next Generation Sequencing Technologies – Speed and Cost .....	90
Table 10 - Global Cancer Panel Market by Region.....	363
Table 11 Global Market by Cancer Type .....	365
Table 12 Global Market by Application.....	371
Table 13 Global Market by Tissue .....	377
Table 14 Global Market Germline & Somatic .....	383
Table 15 Comprehensive Testing by Country.....	390
Table 16 Breast Cancer Gene Testing by Country.....	392
Table 17 Colorectal Cancer Gene Testing by Country.....	394
Table 18 Gynecological Cancer Testing by Country .....	396
Table 19 Blood Cancer Gene Testing by Country .....	398
Table 20 Prostate Cancer Gene Testing by Country .....	400
Table 21 Lung Cancer Gene Testing by Country.....	402

Table 22 Other Cancer Gene Testing by Country .....	404
Table 23 Clinical Testing by Country .....	407
Table 24 Pharmaceutical Testing by Country .....	409
Table 25 Research Testing by Country .....	411
Table 26 Solid Tissue Testing by Country.....	414
Table 27 Liquid Tissue Testing by Country .....	416
Table 28 Somatic by Country .....	419
Table 29 Germline by Country .....	421
Table 30 Potential Screening Market: Lung, Breast & Colorectal.....	424
Table 31 Potential Screening Market: Prostate, Other & All .....	426
Table 32 Potential Cancer Diagnosis Market Size .....	428
Table 33 Potential Cancer Management Market Size .....	430
Table 34 Foundation - Guardant 2016-17 Quarterly Revenue & Volume .....	433
Table 35 Foundation - Guardant 2018 Quarterly Revenue & Volume .....	434
Table 36 Foundation - Guardant 2019 Quarterly Revenue & Volume .....	435
Table 37 Foundation - Guardant 2020 Quarterly Revenue & Volume .....	436
Table 38 Foundation - Guardant 2021 Quarterly Revenue & Volume .....	437
Table 39 2022 Laboratory Fee Schedule .....	438
Table 40 FDA Approved Human Genetic tests .....	540
Table 41 Pharmacogenomic Biomarkers .....	546
Table 42 FDA Approved Pharmacogenomic Tests.....	569

## Table of Figures

Figure 1 Large Comprehensive Profiles – Company Market Shares Chart .....	34
Figure 2 VistSeq Hereditary Cancer Panel.....	38
Figure 3 Global Healthcare Spending .....	45
Figure 4 The Wholesale and Retail Lab Test Pie .....	46
Figure 5 The Genomic Progression of Cancer.....	56
Figure 6 DNA Strands and Chromosomes .....	57
Figure 7 Karyogram of Human Chromosomes.....	58
Figure 8 Size of Various Genomes .....	61
Figure 9 Germline vs Somatic Mutations.....	65
Figure 10 Comparing Genomic Diagnostic and Traditional Testing .....	69
Figure 11 Percentage of World Population Over 65.....	85
Figure 12 Base Year Country Global Share .....	364
Figure 13 Global Market by Cancer - Base vs. Final Year .....	366
Figure 14 Cancer Panel Market Base Year.....	367
Figure 15 Cancer Panel Market Final Year .....	368
Figure 16 Cancer Type Share by Year .....	369
Figure 17 Cancer Type Segment Growth .....	370
Figure 18 Global Market by Cancer - Base vs. Final Year .....	372
Figure 19 Cancer Panel Market Base Year.....	373
Figure 20 Cancer Panel Market Final Year .....	374
Figure 21 Application Share by Year.....	375

Figure 22 Application Segment Growth .....	376
Figure 23 Global Market by Cancer - Base vs. Final Year .....	378
Figure 24 Cancer Panel Market Base Year.....	379
Figure 25 Cancer Panel Market Final Year .....	380
Figure 26 Tissue Share by Year .....	381
Figure 27 Tissue Segment Growth.....	382
Figure 28 Germline & Somatic - Base vs. Final Year .....	384
Figure 29 Germline & Somatic Market Base Year .....	385
Figure 30 Germline & Somatic Market Final Year.....	386
Figure 31 Germline & Somatic Share by Year .....	387
Figure 32 Germline & Somatic Segment Growth .....	388
Figure 33 Comprehensive Testing Growth.....	391
Figure 34 Breast Cancer Testing Growth.....	393
Figure 35 Colorectal Cancer Gene Testing Growth .....	395
Figure 36 Gynecological Cancer Testing Growth .....	397
Figure 37 Blood Cancer Gene Testing Growth .....	399
Figure 38 Prostate Cancer Gene Testing Growth .....	401
Figure 39 Lung Cancer Gene Testing Growth.....	403
Figure 40 Other Cancer Gene Testing Growth .....	405
Figure 41 Clinical Testing Growth .....	408
Figure 42 Pharmaceutical Testing Growth.....	410
Figure 43 Research Testing Growth .....	412
Figure 44 Solid Tissue Testing Growth.....	415
Figure 45 Liquid Tissue Testing Growth.....	417

Figure 46 Somatic Testing Growth..... 420

Figure 47 Germline Testing Growth ..... 422